scholarly article | Q13442814 |
P50 | author | Thai Huu Ho | Q57130809 |
James J Hsieh | Q88029561 | ||
Morgan Rouprêt | Q88883209 | ||
P2093 | author name string | Satish K Tickoo | |
Jean-Philippe Spano | |||
Hui Yao | |||
David Khayat | |||
Xiaoping Su | |||
Paul Russo | |||
Ying-Bei Chen | |||
Yiyu Dong | |||
Eva Compérat | |||
Jose A Karam | |||
Nizar M Tannir | |||
Roger Mouawad | |||
Ronan Flippot | |||
Gabriel G Malouf | |||
Kyle A Blum | |||
Roy Mano | |||
Abraham A Hakimi | |||
Renzo G Dinatale | |||
P2860 | cites work | Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 |
Integrated molecular analysis of clear-cell renal cell carcinoma | Q27852382 | ||
A method and server for predicting damaging missense mutations | Q27860835 | ||
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas | Q33688439 | ||
KRAS and YAP1 converge to regulate EMT and tumor survival | Q33946244 | ||
Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription | Q34074890 | ||
Signaling pathways in renal cell carcinoma | Q34978827 | ||
Predicting the functional impact of protein mutations: application to cancer genomics | Q35224321 | ||
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology | Q35584856 | ||
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain | Q36236290 | ||
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair | Q36320349 | ||
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma | Q36365688 | ||
Chromatin remodeling in cancer: a gateway to regulate gene transcription | Q36511855 | ||
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma | Q36646352 | ||
Twist-mediated Epithelial-mesenchymal Transition Promotes Breast Tumor Cell Invasion via Inhibition of Hippo Pathway | Q36814799 | ||
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. | Q37330688 | ||
The Hippo pathway and human cancer. | Q38087215 | ||
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters | Q38136413 | ||
Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape | Q38678106 | ||
mTOR Signaling in Growth, Metabolism, and Disease. | Q38747508 | ||
YAP modulates TGF-β1-induced simultaneous apoptosis and EMT through upregulation of the EGF receptor | Q38829202 | ||
Hippo signaling in the kidney: the good and the bad. | Q38838116 | ||
The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. | Q38907037 | ||
A conditional mouse model for malignant mesothelioma | Q40004544 | ||
Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers | Q41871593 | ||
Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib | Q44269222 | ||
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy | Q46209280 | ||
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. | Q47631332 | ||
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. | Q47916891 | ||
NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas | Q48015099 | ||
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. | Q52321029 | ||
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. | Q52642770 | ||
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. | Q52726723 | ||
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer | Q58093858 | ||
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples | Q88627382 | ||
P433 | issue | 1 | |
P921 | main subject | renal cell carcinoma | Q1164529 |
P304 | page(s) | 701 | |
P577 | publication date | 2020-01-20 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers | |
P478 | volume | 10 |
Q90690759 | Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations |
Q100533974 | Sarcomatoid renal cell carcinoma: biology, natural history and management |
Q97523716 | The Effect of Chinese Traditional Medicine Huaiqihuang (HQH) on the Protection of Nephropathy |
Q95645882 | The Hippo Pathway as a Driver of Select Human Cancers |
Search more.